Related Experiment Video
Updated: Feb 3, 2026

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Periprocedural antibiotic treatment in transvascular aortic valve replacement
Bruna Gomes1, Nicolas A Geis1, Florian Leuschner1
1Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
Background:
To date, there are no guidelines recommending a specific prophylactic antibiotic treatment in transcatheter aortic valve replacement (TAVR). The aim of this study is to evaluate clinical data after TAVR with different periprocedural antibiotic regimens.
Methods:
In May 2015 the institutional rules for periprocedural antibiotic prophylaxis were changed from 3 days to 1 day. Thus, a total of 450 consecutive TAVR patients between February 2014 and June 2016 were classified into two intention-to-treat groups: patients receiving a 1-day Cefuroxime prophylaxis (N = 225); patients receiving a 3-day Cefuroxime prophylaxis (N = 225).
Results:
One-day Cefuroxime regimen was not associated with shorter hospitalization (3-day Cefuroxime 9 ± 4.7 vs 1-day Cefuroxime 8.9 ± 4.0; P = 0.87). Incidence of diarrhea (26.2% vs 18.2%; P = 0.04) and Clostridium difficile infections (4% vs 0.4%; P = 0.01) were significantly higher in the 3-day group. No endocarditis was registered after 1 year follow-up. There was no difference in 30-day overall mortality rate, major vascular complications, bleeding complications, pacemaker-implantation rate, paravalvular regurgitation, or acute kidney injury between patients groups.
Conclusion:
Three-day Cefuroxime prophylaxis does not seem to be advantageous compared to a shorter 1-day regimen, but even shows a significantly higher incidence of diarrhea and Clostridium difficile infection.
Insights
A 1-day Cefuroxime antibiotic regimen for transcatheter aortic valve replacement (TAVR) is as effective as a 3-day regimen. The shorter regimen significantly reduces the risk of diarrhea and Clostridium difficile infections.
Area of Science:
- Cardiology
- Infectious Diseases
- Surgical Prophylaxis
Background:
- Current guidelines lack specific antibiotic prophylaxis recommendations for transcatheter aortic valve replacement (TAVR).
- This study evaluates clinical outcomes associated with different periprocedural antibiotic regimens in TAVR patients.
Purpose of the Study:
- To compare the efficacy and safety of 1-day versus 3-day Cefuroxime prophylaxis in TAVR procedures.
- To assess the impact of antibiotic duration on hospitalization, infection rates, and other clinical outcomes.
Main Methods:
- A total of 450 consecutive TAVR patients were analyzed.
- Patients were divided into two groups: 1-day Cefuroxime prophylaxis (N=225) and 3-day Cefuroxime prophylaxis (N=225).
- Data were collected between February 2014 and June 2016, following a change in institutional antibiotic prophylaxis rules in May 2015.
Main Results:
- Hospitalization duration was similar between the 1-day and 3-day Cefuroxime groups (8.9 ± 4.0 vs. 9 ± 4.7 days, P=0.87).
- The 3-day Cefuroxime group showed significantly higher incidences of diarrhea (26.2% vs. 18.2%, P=0.04) and Clostridium difficile infections (4% vs. 0.4%, P=0.01).
- No significant differences were observed in 30-day mortality, major vascular complications, bleeding, pacemaker implantation, paravalvular regurgitation, or acute kidney injury.
Conclusions:
- A 3-day Cefuroxime prophylaxis regimen offers no apparent advantage over a 1-day regimen in TAVR patients.
- The shorter 1-day regimen is associated with a lower incidence of gastrointestinal side effects, including diarrhea and C. difficile infections.
More Related Videos
Related Concept Videos
Antibiotic Selection
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Continuous Renal Replacement Therapy
Development of Antibiotic Resistance
Mitral Valve Prolapse I: Introduction
Aortic Regurgitation I: Introduction

